Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis

ConclusionsGiven the limited activity of ceftriaxone againstS. aureus, particularly for serious infections when bacterial kill is desired, the convenience of once-daily dosing should be weighed against the risks of using an overly broad, suboptimal therapy. Cefazolin warrants further consideration, particularly as optimal pharmacodynamics against MSSA may be achieved with twice-daily dosing in most patients.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research